Market Overview

Alnylam Pharma Reports Offering of $125M in Stock

Share:
Related ALNY
Alnylam Initiates Phase 3 Open Label Extension Study with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR Amyloidosis)
5 Biotech Stocks On Deck With The FDA
Alnylam initiates Phase 1/2 ALN-AAT trial in liver disease (Seeking Alpha)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $125 million. All of the shares in the offering are to be sold by Alnylam.

Posted-In: News Offerings

 

Related Articles (ALNY)

Get Benzinga's Newsletters